Catalyst
Slingshot members are tracking this event:
FDA Grants Breakthrough Therapy Status to Novartis' (NVS) CTL019 in Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| NVS |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 18, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Fda, Breakthrough Therapy Status, Ctl019, Refractory Diffuse Large B Cell Lymphoma, R/r Dlbcl
